Get started
Author

Bhaktasharan Patel

Observed names: Bhaktasharan C Patel, Bhaktasharan C. Patel, bhaktasharan patel
OpenAlex ID: A5075040289
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
2022 · Bruce E Sands, Peter M Irving, et al. · The Lancet · 308
PDF
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
2023 · Brian G Feagan, Bruce E Sands, et al. · ˜The œLancet. Gastroenterology & hepatology · 246
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134
PDF
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 113
PDF
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Laurent Peyrin-Biroulet, Jessica R. Allegretti, et al. · Gastroenterology · 104
PDF
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
2021 · Laurent Peyrin-Biroulet, Ailsa Hart, et al. · ˜The œLancet. Gastroenterology & hepatology · 97
PDF
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
2020 · Catherine Frenette, Zeid Kayali, et al. · Journal of Hepatology · 62
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
2025 · Cynthia Levy, George F. Abouda, et al. · Journal of Hepatology · 27
PDF
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection
2022 · Cynthia Portal-Celhay, Eduardo Forleo-Neto, et al. · JAMA Network Open · 17
PDF
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
2026 · Millie Long, Jessica R Allegretti, et al. · ˜The œLancet. Gastroenterology & hepatology · 9
OS-089 Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial
2025 · Cynthia Levy, George Abouda, et al. · Journal of Hepatology · 4
Initial Clinical Experience With the Oral Cholate Challenge Test: Results From the 2023–2024 Early Access Program
2025 · Stuart C. Gordon, James Burton, et al. · Liver international communications. · 3
PDF
Cannabinoids in Gastrointestinal Disorders
2020 · Michelle Kem Su Hor, Monica Dzwonkowski, et al. · Springer eBooks · 3
Cholate Clearance: Improving the Assessment of Liver Health Compared to Current Liver Tests
2025 · James R. Burton, Edward Mena, et al. · Gastro Hep Advances · 2
O51 Long-term elafibranor in primary sclerosing cholangitis (PSC): interim safety and efficacy data from the ELMWOOD open-label extension (OLE) trial
2026 · Kuldeep Cheent, Christopher L Bowlus, et al.
PDF
Tu2019 CNP-104 DEMONSTRATES ANTIGEN-SPECIFIC IMMUNE TOLERANCE IN PBC VIA PATHOGENIC CYTOKINE REDUCTION AND TOLEROGENIC T CELL EXPANSION
2026 · Adam Elhofy, Christopher L. Bowlus, et al. · Gastrointestinal Endoscopy
Tu2019 CNP-104 DEMONSTRATES ANTIGEN-SPECIFIC IMMUNE TOLERANCE IN PBC VIA PATHOGENIC CYTOKINE REDUCTION AND TOLEROGENIC T CELL EXPANSION
2026 · Adam Elhofy, Christopher L. Bowlus, et al. · Gastroenterology
497 Long-term Data of Elafibranor in Primary Sclerosing Cholangitis: Interim Safety and Efficacy Data From the Ongoing Open-label Extension of the Elmwood Phase Ii Trial
2026 · Christopher L. Bowlus, Cynthia Levy, et al. · Gastrointestinal Endoscopy
Tu2020 CNP-104, AN INVESTIGATIONAL ANTIGEN-SPECIFIC NANOPARTICLE THERAPY, DEMONSTRATES FAVORABLE SAFETY AND EARLY SIGNAL OF DISEASE STABILIZATION IN A PHASE 2A RANDOMIZED, PLACEBO- CONTROLLED TRIAL IN PATIENTS WITH PBC, SUPPORTING ADVANCEMENT TO NEXT PHASE TRIALS
2026 · Christopher L. Bowlus, Adam Elhofy, et al. · Gastrointestinal Endoscopy
Tu2020 CNP-104, AN INVESTIGATIONAL ANTIGEN-SPECIFIC NANOPARTICLE THERAPY, DEMONSTRATES FAVORABLE SAFETY AND EARLY SIGNAL OF DISEASE STABILIZATION IN A PHASE 2A RANDOMIZED, PLACEBO- CONTROLLED TRIAL IN PATIENTS WITH PBC, SUPPORTING ADVANCEMENT TO NEXT PHASE TRIALS
2026 · Christopher L. Bowlus, Adam Elhofy, et al. · Gastroenterology
497 Long-term Data of Elafibranor in Primary Sclerosing Cholangitis: Interim Safety and Efficacy Data From the Ongoing Open-label Extension of the Elmwood Phase Ii Trial
2026 · Christopher L. Bowlus, Cynthia Levy, et al. · Gastroenterology
OS-089 CNP-104, an investigational antigen-specific therapy, demonstrates favorable impact across multiple analyses of liver stiffness measurement in a Phase 2a randomized, placebocontrolled trial in PBC
2026 · Christopher L. Bowlus, Adam Elhofy, et al. · Journal of Hepatology
SAT-282 CNP-104, an investigational antigen-specific therapy, demonstrates evidence of improved hepatic function and prognostic risk in a phase 2a randomized, placebo-controlled trial in PBC
2026 · Christopher L. Bowlus, Adam Elhofy, et al. · Journal of Hepatology
Induction of Antigen-Specific T Cell Tolerance by CNP-104 Positively Affects Clinical Response in Primary Biliary Cholangitis (PBC) 9237
2025 · Adam Elhofy, Christopher Bowlus, et al. · The Journal of Immunology
Mo1685: INDEPENDENT ANALYSIS OF EARLY CLINICAL PRACTICE EXPERIENCE WITH THE HEPQUANT DUO TEST
2025 · Uday Patel, Rutva Nakarani, et al. · Gastroenterology
Works count: 27
Citation count: 1,126
H-index: 9
I10-index: 9
Year
Topic
Type